RegenETP Inc. (RGTPQ)

OTCMKTS: RGTPQ · Delayed Price · USD
0.0203
0.00 (0.00%)
Feb 28, 2024, 1:02 PM EST - Market closed
Market Cap 66.39K
Revenue (ttm) 73,000
Net Income (ttm) -8.31M
Shares Out 7.32M
EPS (ttm) -1.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,768
Open 0.0999
Previous Close n/a
Day's Range 0.0203 - 0.0999
52-Week Range n/a
Beta 0.82
Analysts n/a
Price Target n/a
Earnings Date n/a

About RGTPQ

RegenETP, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, o... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 13, 1999
Employees 42
Stock Exchange OTCMKTS
Ticker Symbol RGTPQ
Full Company Profile

Financial Performance

In 2022, RegenETP's revenue was $814,000, a decrease of -91.34% compared to the previous year's $9.40 million. Losses were -$7.83 million, -74.05% less than in 2021.

Financial Statements

News

PolarityTE Announces Entry Into a Letter of Intent For Acquisition of the Company

SALT LAKE CITY , Dec. 27, 2022 /PRNewswire/ --  PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials (the "Company"), today announced that i...

1 year ago - PRNewsWire

PolarityTE Reports Third Quarter 2022 Financial Results and Provides Business Update

SALT LAKE CITY , Nov. 10, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and rep...

1 year ago - PRNewsWire

PolarityTE Confirms Receipt of Unsolicited, Non-Binding Offer to Acquire the Company

SALT LAKE CITY , Nov. 9, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today confirmed that on November 1, 2022...

1 year ago - PRNewsWire

PolarityTE to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022

SALT LAKE CITY , Sept. 13, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced it will present at the...

1 year ago - PRNewsWire

PolarityTE Announces Resignation of Jeff Dyer from its Board of Directors

SALT LAKE CITY , Sept. 8, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that Jeff Dyer, PhD, has...

1 year ago - PRNewsWire

PolarityTE Reports Second Quarter 2022 Financial Results and Provides Business Update

PolarityTE to host conference call and webcast today, August 11, 2022, at 4:30 p.m. ET SALT LAKE CITY , Aug. 11, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing ...

1 year ago - PRNewsWire

PolarityTE to Report Q2 2022 Financial Results on August 11, 2022

SALT LAKE CITY , Aug. 1, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ: PTE) today announced that it will report results for the quarter ended June 30, 2022, by press release on Thursday, August 11, 2...

1 year ago - PRNewsWire

PolarityTE Announces $8.0 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

SALT LAKE CITY , June 6, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it has entered into...

1 year ago - PRNewsWire

PolarityTE to Attend H.C. Wainwright Global Investment Conference

SALT LAKE CITY , May 23, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that Richard Hague, Chief Executive Officer, and Nikolai Sopko, MD, PhD, Chief Scientific Officer, will pre...

1 year ago - PRNewsWire

PolarityTE to Effectuate 1-for-25 Reverse Stock Split

SALT LAKE CITY , May 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that the Company will eff...

1 year ago - PRNewsWire

PolarityTE Reports First Quarter 2022 Financial Results and Provides Business Update

PolarityTE to host conference call and webcast today, May 16, 2022, at 8:30 a.m. ET SALT LAKE CITY , May 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing rege...

1 year ago - PRNewsWire

PolarityTE Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE®

SALT LAKE CITY , May 13, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that the U.S. Food and Drug Administration (FDA) granted a Regenerative Medicine Advanced Therapy (RMAT) de...

1 year ago - PRNewsWire

PolarityTE to Report Q1 2021 Financial Results on May 16, 2022

SALT LAKE CITY , May 6, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the three-month period ended March 31, 2022, by press release on Monday, May...

1 year ago - PRNewsWire

PolarityTE Announces First Subject Enrolled in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers

SALT LAKE CITY , May 3, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced the enrollment of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational ...

1 year ago - PRNewsWire

Why Is PolarityTE Stock Up 85% Today?

PolarityTE Inc (NASDAQ: PTE) shares are surging Tuesday as traders circle bullish commentary from a popular trader in the "FinTwit" community. "FinTwit" is an abbreviated term for "Financial Twitter,"...

2 years ago - Benzinga

PolarityTE Reports Fiscal Year 2021 Financial Results and Provides Business Update

PolarityTE to host conference call and webcast today, March 30, 2022, at 8:30 a.m. ET SALT LAKE CITY , March 30, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing ...

2 years ago - PRNewsWire

PolarityTE Announces Closing of $5.0 Million Registered Direct Offering

SALT LAKE CITY, March 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) ("PolarityTE" or the "Company"), a biotechnology company developing regenerative tissue products and biomaterials, today a...

2 years ago - PRNewsWire

PolarityTE Announces $5.0 Million Registered Direct Offering

SALT LAKE CITY, March 16, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) ("PolarityTE" or the "Company"), a biotechnology company developing regenerative tissue products and biomaterials, today a...

2 years ago - PRNewsWire

PolarityTE to Report Fiscal Year 2021 Financial Results on March 30, 2022

SALT LAKE CITY, March 10, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the year ended December 31, 2021, by press release on Wednesday, March 30,...

2 years ago - PRNewsWire

PolarityTE's SkinTE Meets Primary, Secondary Goals In Venous Leg Ulcers Trial

PolarityTE Inc (NASDAQ: PTE) has announced results from a multi-center randomized controlled trial evaluating SkinTE for Venous Leg Ulcers (VLU). There were twenty-nine participants, with 14 receiving...

2 years ago - Benzinga

PolarityTE Announces Allowance of Fourth U.S. Patent

SALT LAKE CITY, Feb. 17, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced the U.S. Patent and Trad...

2 years ago - PRNewsWire

FDA Approves PolarityTE's Phase 3 Study Of SkinTE In Chronic Cutaneous Ulcer

The FDA has signed off PolarityTE Inc's (NASDAQ: PTE) investigational new drug (IND) application to evaluate SkinTE to treat chronic cutaneous ulcers.  This follows the Company satisfactorily addressi...

2 years ago - Benzinga

PolarityTE Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication

SALT LAKE CITY, Jan. 18, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced that the U.S. Food and D...

2 years ago - PRNewsWire

PolarityTE Announces Submission of Complete Response to FDA's Clinical Hold Correspondence for SkinTE® Investigational New Drug Application

SALT LAKE CITY, Dec. 20, 2021 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that it has submitted its...

2 years ago - PRNewsWire

POLARITYTE ALERT: Bragar Eagel & Squire, P.C. is Investigating PolarityTE, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #PTE--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against PolarityTE, Inc. (NASDAQ: PTE) on behalf o...

2 years ago - Business Wire